^
    1d
    CAMPERR: cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (clinicaltrials.gov)
    P=N/A, N=7000, Recruiting, Adela, Inc | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Minimal residual disease
    1d
    Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision (clinicaltrials.gov)
    P=N/A, N=20, Enrolling by invitation, Guangdong Provincial Hospital of Traditional Chinese Medicine
    New trial
    1d
    Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) (clinicaltrials.gov)
    P2, N=178, Active, not recruiting, Dartmouth-Hitchcock Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2026 --> Apr 2025
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    letrozole
    4d
    A CARM1-targeted therapeutic peptide suppresses breast cancer progression both in vitro and in vivo. (PubMed, Pharmacol Res)
    Notably, the combination of Pi-CARM1-TAT with endocrine therapy drugs or etoposide shows synergistic effects in inhibiting breast tumorigenesis. Furthermore, Pi-CARM1-TAT effectively overcomes endocrine therapy resistance in ER-positive breast cancer cells. In conclusion, we present a novel peptide inhibitor of CARM1, which provides valuable insights and may offer therapeutic potential for the development of CARM1-targeted treatments in breast cancer.
    Preclinical • Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    etoposide IV
    5d
    Subtype Change and Treatment Refractoriness at the Time of Recurrence in a Patient with Breast Cancer (PubMed, Gan To Kagaku Ryoho)
    At the time of tracheotomy, biopsy evaluation revealed that the metastatic left supraclavicular lymph nodes were ER- and HER2-positive; therefore, the treatment was switched to a trastuzumab, pertuzumab, and docetaxel(TPD)combination for HER2-positive recurrent breast cancer. However, PET-CT revealed increased accumulation in the recurrent lesions, and the treatment was switched to trastuzumab deruxtecan (T-DXd). The accumulation of recurrent foci became less pronounced and the patient continued to progress without further deterioration.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    5d
    Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery (clinicaltrials.gov)
    P4, N=160, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, Orano Med LLC | Trial completion date: Aug 2027 --> May 2032 | Trial primary completion date: Aug 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    212Pb-DOTAM-GRPR1
    7d
    PreEMBER: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (clinicaltrials.gov)
    P2, N=600, Not yet recruiting, Eli Lilly and Company | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    tamoxifen • Inluriyo (imlunestrant) • goserelin acetate
    7d
    EVOLVE-BDT: Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (clinicaltrials.gov)
    P2, N=700, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial
    |
    Tempus xR
    |
    everolimus • capecitabine • Verzenio (abemaciclib)
    8d
    PilatesBCS2026: Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Benha University | Not yet recruiting --> Recruiting
    Enrollment open
    8d
    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, University of Miami | Recruiting --> Active, not recruiting | N=500 --> 24
    Enrollment closed • Enrollment change • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • everolimus • tamoxifen • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • Truqap (capivasertib) • letrozole • anastrozole • exemestane • Orserdu (elacestrant) • Navelbine oral (vinorelbine tartrate oral)
    9d
    The miRNA-4330/ABCG2 axis overcomes drug resistance and cancer progression in both ER-positive and ER-negative resistant breast cancer cells. (PubMed, Clin Transl Oncol)
    The current findings identified miR-4330 restoration as a tool for overcoming acquired drug resistance and reducing cancer activity, which might be used to improve therapeutic strategies and treatment regimens for breast cancer patients. miR-4330 may be useful as a diagnostic and prognostic marker for drug-resistant breast cancer.
    Journal
    |
    ER (Estrogen receptor) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • MIR433 (MicroRNA 433)
    |
    ER positive • ER negative
    |
    doxorubicin hydrochloride